WO2008005880A3 - Antibodies for norovirus - Google Patents

Antibodies for norovirus Download PDF

Info

Publication number
WO2008005880A3
WO2008005880A3 PCT/US2007/072559 US2007072559W WO2008005880A3 WO 2008005880 A3 WO2008005880 A3 WO 2008005880A3 US 2007072559 W US2007072559 W US 2007072559W WO 2008005880 A3 WO2008005880 A3 WO 2008005880A3
Authority
WO
WIPO (PCT)
Prior art keywords
norovirus
peptides
antibodies
detection
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/072559
Other languages
French (fr)
Other versions
WO2008005880A2 (en
Inventor
Jane Catherine Frye
Hoshin Park
Myung L Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KIM LABORATORIES
KIM LAB
Original Assignee
KIM LABORATORIES
KIM LAB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KIM LABORATORIES, KIM LAB filed Critical KIM LABORATORIES
Priority to EP07799211A priority Critical patent/EP2049152A2/en
Priority to US12/306,818 priority patent/US8066998B2/en
Priority to JP2009518589A priority patent/JP2009542715A/en
Publication of WO2008005880A2 publication Critical patent/WO2008005880A2/en
Publication of WO2008005880A3 publication Critical patent/WO2008005880A3/en
Anticipated expiration legal-status Critical
Priority to US13/253,277 priority patent/US20120020964A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/106—Picornaviridae (F), e.g. hepatitis A virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Norovirus antigen peptides are described having an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-16, or fragments thereof. Such peptides can be used in the preparation of antiviral therapies such as vaccines, methods of preparing antibodies to the antigen peptides, methods of using the peptides or the corresponding antibodies for detection of norovirus, and compositions of the peptides, DNA and/or antibodies. A kit for the detection of norovirus is also provided.
PCT/US2007/072559 2006-06-30 2007-06-29 Antibodies for norovirus Ceased WO2008005880A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP07799211A EP2049152A2 (en) 2006-06-30 2007-06-29 Antibodies for norovirus
US12/306,818 US8066998B2 (en) 2006-06-30 2007-06-29 Antibodies for norovirus
JP2009518589A JP2009542715A (en) 2006-06-30 2007-06-29 Norovirus antibody
US13/253,277 US20120020964A1 (en) 2006-06-30 2011-10-05 Antibodies for Norovirus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81806906P 2006-06-30 2006-06-30
US60/818,069 2006-06-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/253,277 Continuation US20120020964A1 (en) 2006-06-30 2011-10-05 Antibodies for Norovirus

Publications (2)

Publication Number Publication Date
WO2008005880A2 WO2008005880A2 (en) 2008-01-10
WO2008005880A3 true WO2008005880A3 (en) 2008-07-24

Family

ID=38895384

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/072559 Ceased WO2008005880A2 (en) 2006-06-30 2007-06-29 Antibodies for norovirus

Country Status (5)

Country Link
US (2) US8066998B2 (en)
EP (1) EP2049152A2 (en)
JP (1) JP2009542715A (en)
KR (1) KR20090039707A (en)
WO (1) WO2008005880A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2010085790A1 (en) * 2009-01-26 2010-07-29 Baylor College Of Medicine A single chain antibody for the detection of noroviruses
KR101086879B1 (en) * 2010-03-26 2011-11-24 재단법인서울대학교산학협력재단 Norovirus detection antibody, and norovirus detection method using the same
KR101025596B1 (en) * 2010-03-26 2011-03-30 재단법인서울대학교산학협력재단 Specific for norovirus and method of detecting various norovirus
WO2013039165A1 (en) 2011-09-13 2013-03-21 デンカ生研株式会社 Anti-human norovirus gii antibody
US20140017257A1 (en) * 2012-07-11 2014-01-16 Xi Jiang IgY From Norovirus P Particles And Their Derivatives
EP3583950A1 (en) * 2013-05-09 2019-12-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use
JP6574119B2 (en) * 2015-08-31 2019-09-11 大王製紙株式会社 Norovirus inactivation evaluation method
WO2018074558A1 (en) * 2016-10-23 2018-04-26 デンカ株式会社 Composite polypeptide monomer, aggregate of said composite polypeptide monomer having cell penetration function, and norovirus component vaccine for subcutaneous, intradermal, percutaneous, or intramuscular administration and having said aggregate as effective component thereof
US11833198B2 (en) 2017-03-28 2023-12-05 Children's Hospital Medical Center Norovirus S particle based vaccines and methods of making and using same
CN109957014B (en) * 2017-12-25 2022-03-29 中国科学院上海巴斯德研究所 Preparation and application of anti-norovirus GII.3 murine monoclonal antibody
CN109265542B (en) * 2018-09-27 2021-06-15 国药中生生物技术研究院有限公司 Antibody specifically binding norovirus GII.4 genotype VP1 protein or VLP, and preparation method and application thereof
US20240230649A1 (en) 2021-05-20 2024-07-11 Denka Company Limited Anti-norovirus antibody
JP7884510B2 (en) 2021-05-20 2026-07-03 デンカ株式会社 Anti-norovirus antibodies
CN113740530A (en) * 2021-08-30 2021-12-03 广东省科学院微生物研究所(广东省微生物分析检测中心) ELISA method and kit for panoramic identification of broad-spectrum property of humanized norovirus antibody
CN120829501B (en) * 2025-09-16 2026-03-20 安徽智飞龙科马生物制药有限公司 Anti-GII.6 Norovirus Antibody or its Antigen-Binding Fragment, its Preparation Method and Application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002019986A1 (en) * 2000-09-08 2002-03-14 Epimmune Inc. Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions
WO2005030806A2 (en) * 2003-09-24 2005-04-07 Montana State University Norovirus monoclonal antibodies and peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002019986A1 (en) * 2000-09-08 2002-03-14 Epimmune Inc. Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions
WO2005030806A2 (en) * 2003-09-24 2005-04-07 Montana State University Norovirus monoclonal antibodies and peptides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LOCHRIDGE VANCE P ET AL: "Epitopes in the P2 domain of norovirus VP1 recognized by monoclonal antibodies that block cell interactions", JOURNAL OF GENERAL VIROLOGY, vol. 86, no. Part 10, October 2005 (2005-10-01), pages 2799 - 2806, XP002470340, ISSN: 0022-1317 *
PARKER TRACY DEWESE ET AL: "Identification of genogroup I and genogroup II broadly reactive epitopes on the norovirus capsid", JOURNAL OF VIROLOGY, vol. 79, no. 12, June 2005 (2005-06-01), pages 7402 - 7409, XP002470341, ISSN: 0022-538X *
SHIOTA TOMOYUKI ET AL: "Characterization of a broadly reactive monoclonal antibody against norovirus genogroups I and II: recognition of a novel conformational epitope.", JOURNAL OF VIROLOGY NOV 2007, vol. 81, no. 22, November 2007 (2007-11-01), pages 12298 - 12306, XP009096371, ISSN: 0022-538X *
YODA TOMOKO ET AL: "Precise characterization of norovirus (Norwalk-like virus)-specific monoclonal antibodies with broad reactivity.", JOURNAL OF CLINICAL MICROBIOLOGY JUN 2003, vol. 41, no. 6, June 2003 (2003-06-01), pages 2367 - 2371, XP002470342, ISSN: 0095-1137 *

Also Published As

Publication number Publication date
US8066998B2 (en) 2011-11-29
EP2049152A2 (en) 2009-04-22
US20100215649A1 (en) 2010-08-26
US20120020964A1 (en) 2012-01-26
KR20090039707A (en) 2009-04-22
JP2009542715A (en) 2009-12-03
WO2008005880A2 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
WO2011146891A3 (en) High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
WO2008074867A3 (en) Anti-fc-receptor single domain antibodies (nanobodies-tm) and therapeutic use
WO2008145401A3 (en) Mutated parvovirus structural proteins as vaccines
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
WO2008076255A3 (en) Canine thymic stromal lymphopoietin protein and uses thereof
WO2007119011A3 (en) N protein fusion proteins of a virus in the paramyxoviridae-protein of interest family
WO2010135431A3 (en) Compositions, devices, and methods related to prostate-specific membrane antigen
WO2012054929A3 (en) Use of human serum albumin to decrease antigenicity of therapeutic proteins
WO2010120514A3 (en) Antigen-binding proteins comprising recombinant protein scaffolds
NZ625630A (en) Human il-23 antigen binding proteins
NZ595707A (en) Cancer antigen helper peptide
WO2011153400A3 (en) Nasal immunization
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
WO2009037297A3 (en) Method for the preparation of new oligoclonal antibodies
MXPA06008217A (en) Lawsonia intracellularis subunit vaccines.
WO2010133668A3 (en) Eukaryotic host cell comprising an expression enhancer
WO2005026200A3 (en) Lawsonia intracellularis subunit vaccine
WO2007064844A3 (en) Anti-viral griffithsin compounds, compositions, and methods of use
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
PH12013502292A1 (en) Protein f - a novel haemophilus influenzae adhesin with laminin and vitronectin binding properties
WO2008002548A3 (en) Novel human acidic mammalian chitinase and use thereof
WO2009060710A1 (en) Peptide imparting antibody-binding ability to liposome and liposome modified with the same
WO2004092195A3 (en) Dendritic cell binding proteins and uses thereof
GB2429711A (en) Heart and skeletal muscle inflammation (HSMI) virus

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2009518589

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12306818

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020097000167

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007799211

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07799211

Country of ref document: EP

Kind code of ref document: A2